U.S. Department of Health and Human Services
Clinical Trials Search Results
Search results 1 - 10 of 20 for FDA-Approved Opportunistic Infection and Coinfection Drugs, Harvoni
Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection
Condition: Viral Hepatitis C; HIV
NCT ID: NCT02125500- Red stop iconCompleted
- Email this trial
Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia
Condition: HCV HIV
NCT ID: NCT02339038- Red stop iconActive, not recruiting
- Text file iconHas Results
- Email this trial
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection
Condition: Hepatitis C Infection With HIV Co-Infection
NCT ID: NCT02457611- Red stop iconCompleted
- Text file iconHas Results
- Email this trial
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
Condition: Hepatitis C Virus; HIV
NCT ID: NCT02073656- Red stop iconCompleted
- Text file iconHas Results
- Email this trial
HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection
Condition: Human Immunodeficiency Virus; Hepatitis C, Chronic
NCT ID: NCT02660905- Red stop iconActive, not recruiting
- Email this trial
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
Condition: HIV; Hepatitis C; Cirrhosis
NCT ID: NCT02533934- Green tick iconRecruiting
- Email this trial
Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)
Condition: Hepatitis C; HIV Coinfection
NCT ID: NCT03126370- Green tick iconRecruiting
- Email this trial
Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa
Condition: Hepatitis C; HIV Infection
NCT ID: NCT02405013- Red stop iconCompleted
- Email this trial
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
Condition: HIV-1 Infection; HCV Infection
NCT ID: NCT02707601- Red stop iconCompleted
- Email this trial
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection
Condition: Treatment of Hepatitis C
NCT ID: NCT02480387- Red stop iconCompleted
- Email this trial
Email Updates
